Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29718845 | 1.00 | CA1 (0.43) | CA1CA2CA9CA12L3MBTL1 | |
| SCHEMBL29718877 | 0.81 | HDAC6 (0.39) | CA1CA2CA9L3MBTL1ALDH1A1 | |
| SCHEMBL19552676 | 0.81 | HDAC6 (0.39) | CA1CA2CA9L3MBTL1ALDH1A1 | |
| SCHEMBL19552041 | 0.81 | HDAC6 (0.39) | CA1CA2CA9ALDH1A1CYP3A4 | |
| SCHEMBL19552599 | 0.81 | KDM4E (0.57) | CA1CA2CA9L3MBTL1ALDH1A1 | |
| SCHEMBL29718909 | 0.81 | KDM4E (0.57) | CA1CA2CA9L3MBTL1ALDH1A1 | |
| SCHEMBL7897491 | 0.78 | PIK3CD (0.45) | L3MBTL1ALDH1A1POLBMEN1HSP90AA1 | |
| SCHEMBL11594927 | 0.77 | ALDH1A1 (0.50) | L3MBTL1ALDH1A1CYP3A4ALOX15POLB | |
| SCHEMBL16442407 | 0.76 | GUSB (0.54) | L3MBTL1ALDH1A1POLBMEN1HSP90AA1 | |
| SCHEMBL19551983 | 0.73 | TP53 (0.45) | CA1CA2CA9CA12L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115054600-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11524938-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220324807-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| CN-115054600-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114984003-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-109415321-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-3763704-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2021-01-13 | — | — | EP | disclosed |
| US-10844016-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-11-24 | — | — | US | disclosed |
| EP-3458443-B1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma AG (DE) | 2020-08-19 | — | — | EP | disclosed |
| US-20190119210-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-04-25 | — | — | US | disclosed |
| EP-3458443-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017191000-A9 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-27 | — | — | WO | disclosed |
| WO-2017191000-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119210-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | CA1 3821/4885CA2 2486/4885CA9 918/4885 |
| US-20220324807-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | CA1 3821/4885CA2 2486/4885CA9 918/4885 |
| US-11524938-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | CA1 3821/4885CA2 2486/4885CA9 918/4885 |
| US-10844016-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | CA1 3821/4885CA2 2486/4885CA9 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.